Evofem Biosciences Signs Agreement with Pharma 1

Evofem Biosciences ( (EVFM) ) has provided an announcement.

On May 19, 2025, Evofem Biosciences entered into a License and Supply Agreement with Pharma 1 Drug Store L.L.C, granting Pharma 1 exclusive rights to develop and market SOLOSEC in the Middle East. This agreement allows Pharma 1 to handle the regulatory approval and commercialization of SOLOSEC, an FDA-approved treatment for bacterial vaginosis and trichomoniasis, in the UAE and other GCC countries. The collaboration aims to address the high prevalence of these conditions in the region, with Evofem supplying the product at cost-plus once approved.

Spark’s Take on EVFM Stock

According to Spark, TipRanks’ AI Analyst, EVFM is a Neutral.

Evofem Biosciences’ overall score is low due to significant financial instability, reflected in negative profit margins and high leverage. While recent strategic moves and sales growth offer some hope, the technical indicators and valuation remain major concerns. The company’s future hinges on successful implementation of cost-reduction strategies and strategic partnerships.

To see Spark’s full report on EVFM stock, click here.

More about Evofem Biosciences

Evofem Biosciences, Inc. is a company focused on women’s sexual and reproductive health, commercializing FDA-approved products like PHEXXI and SOLOSEC. The company has experienced four consecutive years of net sales growth.

Average Trading Volume: 974,941

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.02M

For detailed information about EVFM stock, go to TipRanks’ Stock Analysis page.